RedHill Biopharma

375 articles with RedHill Biopharma

• RedHill Biopharma Ltd. Provides Update On Expansion Of Ongoing RHB-105 Phase 3 Study, Targeting Broadened H. Pylori Indication Authorized By FDA

  8/27/2014

• RedHill Biopharma Ltd. Acquires Option For Phase 2 Pancreatic Cancer Drug RP101

  8/13/2014

• RedHill Biopharma Ltd. Reports Results For The Second Quarter Of 2014

  7/23/2014

• RedHill Biopharma Ltd. To Host Second Quarter 2014 Financial Results Conference Call On July 24, 2014

  7/16/2014

• RedHill Biopharma Ltd. Acquires Phase 2 Oncology Drug MESUPRON® From Wilex AG

  6/30/2014

• RedHill Biopharma Ltd. Announces Positive Preliminary Pre-Clinical Data With RHB-104 For The Treatment Of Type 1 Diabetes

  6/26/2014

• RedHill Biopharma Ltd. To Present At The 2014 Biotechnology Industry Organization (BIO) International Convention

  6/18/2014

• RedHill Biopharma Ltd. To Present At The Wells Fargo Securities 9th Annual Healthcare Conference

  6/11/2014

• RedHill Biopharma Ltd. Announces New RHB-104 Patent In Japan And Provides Update On Phase 3 Crohn's Program

  6/5/2014

• RedHill Biopharma Ltd. To Present At Jefferies and Co. 2014 Global Healthcare Conference

  6/2/2014

• RedHill Biopharma Ltd. Announces FDA Clearance For Phase 3 Study With RHB-102 Planned To Commence In Q3/2014

  5/22/2014

• RedHill Biopharma Ltd. And IntelGenx Corp. Report Positive RHB-103 Bioavailability Study Results In Support Of Planned European Marketing Application In Q3/2014

  5/21/2014

• RedHill Biopharma Ltd. To Present At The Chinabio Partnering Forum 2014

  5/1/2014

• RedHill Biopharma Ltd. Reports Results For The First Quarter Of 2014

  5/1/2014

• RedHill Biopharma Ltd. Reports Successful RHB-102 Bioavailability Clinical Trial And Planned Submission Of European Marketing Application In Q3/2014

  4/30/2014

• RedHill Biopharma Ltd. To Host First Quarter 2014 Financial Results Conference Call On May 1, 2014

  4/29/2014

• IntelGenx Corp. And RedHill Biopharma Ltd. Announce Commencement Of A Bioavailability Study With Anti-Migraine Versafilm™ Product To Support European Marketing Application Planned For Q3/2014

  4/28/2014

• IntelGenx Corp. And RedHill Biopharma Ltd. Provide An Update On FDA's Ongoing Review Of The NDA For Migraine Versafilm™ Product

  4/24/2014

• RedHill Biopharma Ltd. Announces Positive European Scientific Advice Meeting Regarding RHB-102 And Plans To Submit A European Marketing Application

  4/7/2014

• RedHill Biopharma Ltd. To Present At The 26th Annual ROTH Conference

  3/7/2014